Trial on Impact of HealthPROMISE Mobile App on Inflammatory Bowel Disease Care and Quality of Life

NACompletedINTERVENTIONAL
Enrollment

320

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

January 20, 2020

Study Completion Date

January 20, 2020

Conditions
Inflammatory Bowel DiseaseCrohn's DiseaseUlcerative Colitis
Interventions
OTHER

HealthPROMISE users

"Patients using HealthPROMISE will be asked to use the application once every two weeks at a minimum to provide updates on health information. Providers can use the data entered by patients in real time. Patients will get alerts requesting them to contact their providers if their quality of life scores fall below a certain threshold or their symptoms scores are worrisome. Both patients and physicians are also sent regular notifications with data about their own health or health of their patient panel respectively. Both patients and providers are encouraged to use existing communication tools (phone, office visits, personal health records) since direct patient-physician messaging is not provided in the HealthPROMISE platform. Reminders through app, email and SMS will be used to facilitate patient engagement.~Physicians will also be encouraged to check the physician panel to see how patients are doing through weekly updates and monthly quality improvement meetings."

OTHER

Control Group

In order to eliminate a placebo effect, patients in both groups will get an app customized for IBD. Physician and rest of care team will not be blinded since they will use HealthPROMISE dashboard to get alerts and notifications.

Trial Locations (1)

10029

Icahn School of Medicine at Mount Sinai, New York

All Listed Sponsors
lead

Icahn School of Medicine at Mount Sinai

OTHER

NCT02322307 - Trial on Impact of HealthPROMISE Mobile App on Inflammatory Bowel Disease Care and Quality of Life | Biotech Hunter | Biotech Hunter